Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 190 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Phase 1 Australia
South Africa

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Neoplasms Phase 1, Phase 2 United Kingdom
United States
Netherlands
Austria
Spain
View All

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA) United States
Russian Federation
Japan
Portugal
Ireland
Greece
Taiwan
Korea, Republic of
Israel
View All

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor Japan

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

Relapsing Forms of Multiple Sclerosis Spain

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

Multiple Sclerosis (MS) France

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Heart Failure Phase 2 United States

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Moderate-to-severe Plaque Psoriasis Russian Federation

WOE of Anti-CD20 Therapies

Multiple Sclerosis United States

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP) Phase 2 Germany
Canada